Opportunity Information: Apply for PAR 16 337
Apply for PAR 16 337
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.395,.
- This funding opportunity was created on Jun 16, 2016 and posted on Jun 16, 2016.
- Applicants must submit their applications by Jul 16, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $50,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03) (PAR 16-337) is a National Institutes of Health funding opportunity under HHS (agency listing HHS-NIH11) that supports small, targeted research projects examining a practical problem in adolescent vaccination: why a clinician's recommendation for the human papillomavirus (HPV) vaccine sometimes leads to vaccination and sometimes does not. The central focus is on the healthcare delivery system itself and how it can strengthen or weaken the impact of a provider recommendation, recognizing that recommendation quality and follow-through are shaped by real-world clinical workflows, communication patterns, policies, and the settings in which care is delivered.
The opportunity is designed to fund research that looks beyond the simple question of whether providers recommend the vaccine and instead studies the pathway linking the recommendation to actual vaccine uptake. That includes investigating factors that influence whether a recommendation is made, how it is delivered (timing, strength, clarity, and framing), and what happens next in the visit and in subsequent encounters. The FOA explicitly highlights that multiple layers can affect outcomes, including provider characteristics (such as knowledge, communication style, comfort addressing parent concerns, and practice habits), parent or patient characteristics (such as beliefs about vaccines, risk perceptions, trust, prior experiences, and readiness to vaccinate), and clinical setting characteristics (such as practice type, staffing, reminder systems, visit structure, competing demands, and institutional policies). The intent is to generate evidence that can help health systems and clinicians improve HPV vaccination rates among adolescents by making recommendations more consistently and ensuring those recommendations translate into completed vaccination.
Because HPV vaccination sits at the intersection of cancer prevention and routine adolescent immunization, the FOA calls for research teams with cross-cutting expertise. It emphasizes the need for perspectives from cancer prevention, adult and child behavior, immunization promotion, and healthcare delivery research. In practice, this points to studies that may integrate behavioral science with implementation and systems approaches, such as understanding communication barriers, designing and testing workflow supports, or evaluating strategies that help practices deliver strong recommendations and reduce missed opportunities for vaccination.
Mechanistically, this is an R03 grant mechanism, which is commonly used for smaller, time-limited projects such as pilot studies, feasibility assessments, secondary data analyses, or focused intervention development and testing. The listed award ceiling is $50,000, signaling that proposed projects should be narrow in scope and tightly aligned with the core question of how delivery-system factors influence the effectiveness of provider recommendations on HPV vaccine uptake. The opportunity falls under the Health and Education activity areas and is associated with CFDA numbers 93.393 and 93.395, which correspond to NIH program areas related to cancer and prevention research.
Eligibility is broad and includes many types of applicants that commonly participate in public health and health services research. Eligible organizations include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; small businesses; and other entities as permitted by NIH eligibility rules (with the FOA noting an additional information field for clarification). This breadth reflects the reality that HPV vaccine delivery and recommendation practices can be studied in many environments, from pediatric and family medicine practices to school-linked health programs and community health systems.
Key administrative details in the source data indicate the FOA was posted and created on June 16, 2016, with a closing date of July 16, 2019 (original and current closing date both listed as July 16, 2019). In plain terms, this announcement supported applications during that time window and was aimed at generating actionable research evidence on improving adolescent HPV vaccination by strengthening the link between provider recommendation and vaccine uptake within real healthcare delivery settings.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is titled "Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03)" and is identified as PAR 16-337.
Which federal agency is offering this grant opportunity?
This is a National Institutes of Health (NIH) funding opportunity under the U.S. Department of Health and Human Services (HHS). The agency listing shown is HHS-NIH11.
What is the main purpose of this FOA?
The main purpose is to support small, targeted research projects that examine why a clinician's recommendation for the HPV vaccine sometimes results in vaccination and sometimes does not, with a central focus on healthcare delivery system factors that strengthen or weaken the impact of the recommendation.
What problem area is this opportunity trying to address?
It addresses a practical challenge in adolescent vaccination: understanding and improving the pathway from a provider recommendation for the human papillomavirus (HPV) vaccine to actual vaccine uptake in real-world care settings.
What is the central focus of the research encouraged by this FOA?
The central focus is on the healthcare delivery system itself and how real-world workflows, communication patterns, policies, and care settings influence whether provider recommendations translate into completed HPV vaccination.
Does the FOA focus only on whether providers recommend the HPV vaccine?
No. It specifically encourages research that goes beyond whether recommendations occur and instead studies the pathway linking the recommendation to uptake, including how the recommendation is delivered and what happens afterward in the visit and in follow-up encounters.
What aspects of the provider recommendation are highlighted for study?
The FOA highlights studying how recommendations are delivered, including timing, strength, clarity, and framing, as well as factors that influence whether a recommendation is made in the first place.
What kinds of "next steps" after the recommendation does the FOA emphasize?
It emphasizes what happens next within the visit and in subsequent encounters, recognizing that follow-through within clinical processes can determine whether the recommendation leads to vaccination.
What types of factors can influence whether a recommendation leads to vaccination?
The FOA notes that multiple layers can affect outcomes, including provider characteristics, parent or patient characteristics, and clinical setting characteristics within the healthcare delivery system.
What provider characteristics are mentioned as relevant to study?
Examples include provider knowledge, communication style, comfort addressing parent concerns, and practice habits.
What parent or patient characteristics are mentioned as relevant to study?
Examples include beliefs about vaccines, risk perceptions, trust, prior experiences, and readiness to vaccinate.
What clinical setting characteristics are mentioned as relevant to study?
Examples include practice type, staffing, reminder systems, visit structure, competing demands, and institutional policies.
Why does the FOA emphasize the healthcare delivery system?
Because recommendation quality and follow-through are shaped by real-world clinical workflows and settings, the FOA targets delivery-system features that can either support or undermine the effectiveness of provider recommendations.
What is meant by "missed opportunities" for vaccination in this context?
Within the context provided, it refers to situations in clinical care where a recommendation is made (or could be made) but system and workflow factors prevent that recommendation from translating into an actual administered vaccine dose.
What kinds of research team expertise does the FOA encourage?
It calls for cross-cutting expertise spanning cancer prevention, adult and child behavior, immunization promotion, and healthcare delivery research.
What types of research approaches does the FOA suggest could be relevant?
It points toward studies that integrate behavioral science with implementation and systems approaches, such as understanding communication barriers, designing and testing workflow supports, or evaluating strategies that help practices deliver strong recommendations and reduce missed opportunities.
What grant mechanism is used for this opportunity?
This opportunity uses the NIH R03 mechanism.
What does the R03 mechanism imply about project scope?
Based on the description provided, the R03 is intended for smaller, time-limited projects such as pilot studies, feasibility assessments, secondary data analyses, or focused intervention development and testing. The project should be narrow in scope and tightly aligned with the FOA's core research question.
What is the listed award ceiling for this opportunity?
The listed award ceiling is $50,000.
What does the $50,000 ceiling suggest about proposed studies?
It signals that proposed projects should be tightly focused and targeted to the specific question of how delivery-system factors influence the effectiveness of provider recommendations on HPV vaccine uptake.
What activity areas is this opportunity associated with?
It is associated with the Health and Education activity areas.
What CFDA numbers are associated with this funding opportunity?
The opportunity is associated with CFDA 93.393 and 93.395.
How does this FOA connect HPV vaccination to broader public health goals?
The FOA frames HPV vaccination as sitting at the intersection of cancer prevention and routine adolescent immunization, and it aims to generate evidence that helps health systems and clinicians improve adolescent HPV vaccination rates.
What types of organizations are eligible to apply?
Eligibility is broad and includes: state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; small businesses; and other entities as permitted by NIH eligibility rules (with additional information noted for clarification).
Are academic institutions eligible?
Yes. Both public and state-controlled institutions of higher education and private institutions of higher education are listed as eligible.
Are governmental entities eligible?
Yes. State, county, city or township governments, special district governments, and independent school districts are listed as eligible.
Are tribal organizations eligible?
Yes. Federally recognized Native American tribal governments and other Native American tribal organizations are listed as eligible.
Are nonprofits eligible?
Yes. Nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education) are listed as eligible.
Are for-profit organizations eligible?
Yes. For-profit organizations other than small businesses are listed as eligible, and small businesses are also listed as eligible.
What kinds of settings could be appropriate for studying the research questions in this FOA?
The FOA notes that HPV vaccine delivery and recommendation practices can be studied in many environments, including pediatric and family medicine practices, school-linked health programs, and community health systems.
When was this FOA posted and created?
Key administrative details indicate it was posted and created on June 16, 2016.
What was the closing date for this opportunity?
The closing date is listed as July 16, 2019 (both the original and current closing date are shown as July 16, 2019).
What time period did this announcement support applications?
Based on the posted/created date and the closing date provided, it supported applications during the window from June 16, 2016 through July 16, 2019.
In plain terms, what outcome is this FOA trying to achieve through funded research?
It aims to produce actionable research evidence that helps clinicians and health systems improve HPV vaccination rates among adolescents by making recommendations more consistently and improving the likelihood that recommendations lead to completed vaccination.
Browse more opportunities from the same category: Education, Health
Next opportunity: Coastal Impacts Associated with Climate Change
Previous opportunity: EDISON NHS YOUTH INTERNS FOR 2016
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 337
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 337) also looked into and applied for these:
| Funding Opportunity |
|---|
| Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21) Apply for PAR 16 336 Funding Number: PAR 16 336 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01) Apply for PAR 16 338 Funding Number: PAR 16 338 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| U.S.-Russia Bilateral Collaborative Research Partnerships (CRP) on the Prevention and Treatment of HIV/AIDS and HIV-Associated Comorbidities (R01) Apply for RFA AA 17 006 Funding Number: RFA AA 17 006 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Cancer Target Discovery and Development Network (U01) Apply for RFA CA 16 014 Funding Number: RFA CA 16 014 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $750,000 |
| U.S.-Russia Bilateral Collaborative Research Partnerships on Cancer (R21) Apply for RFA CA 16 015 Funding Number: RFA CA 16 015 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $100,000 |
| Limited Competition: The Chernobyl Tissue Bank - Coordinating Center (U24) Apply for RFA CA 16 502 Funding Number: RFA CA 16 502 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24) Apply for RFA CA 16 017 Funding Number: RFA CA 16 017 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $1,000,000 |
| Research Centers for Population-based Research to Optimize Cancer Screening (PROSPR) Initiative (UM1) Apply for RFA CA 16 016 Funding Number: RFA CA 16 016 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $2,500,000 |
| FY 2017 American Schools and Hospitals Abroad (ASHA) Program (Request for Comments) Apply for APS ASHA 17 000001 Funding Number: APS ASHA 17 000001 Agency: Agency for International Development Category: Education, Health Funding Amount: $2,000,000 |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33) Apply for RFA CA 17 013 Funding Number: RFA CA 17 013 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Innovative Technologies for Cancer-Relevant Biospecimen Science (R21) Apply for RFA CA 17 012 Funding Number: RFA CA 17 012 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33) Apply for RFA CA 17 011 Funding Number: RFA CA 17 011 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24) Apply for RFA CA 17 004 Funding Number: RFA CA 17 004 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $650,000 |
| PDX Development and Trial Centers (PDTCs) (U54) Apply for RFA CA 17 003 Funding Number: RFA CA 17 003 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $800,000 |
| Mechanisms of Cancer Drug Resistance and Sensitivity (U54) Apply for RFA CA 17 009 Funding Number: RFA CA 17 009 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $750,000 |
| Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01) Apply for RFA CA 17 015 Funding Number: RFA CA 17 015 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24) Apply for RFA CA 17 016 Funding Number: RFA CA 17 016 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24) Apply for RFA CA 17 002 Funding Number: RFA CA 17 002 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Canine Immunotherapy Trials and Correlative Studies (U01) Apply for RFA CA 17 001 Funding Number: RFA CA 17 001 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp) Apply for PA 17 138 Funding Number: PA 17 138 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $135,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 337", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.